PEGylated cholecystokinin prolongs satiation in rats: Dose dependency and receptor involvement

British Journal of Pharmacology

Volumn 152, Issue 3, 2007, Pages 396-403

  Verbaeys, I ^a   Leon Tamariz F ^a   Buyse, J ^a   De Cuyper, M ^a   Pottel, H ^a   Van Boven, M ^a   Cokelaere, M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anorexia; CCK 1 receptor antagonists; Cholecystokinin; Devazepide 2 NAP; Dose response; PEGylated cholecystokinin

Indexed keywords

2 NAPHTHALENESULPHONYL 1 ASPARTYL(2 PHENETHYL)AMIDE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ DERIVATIVE; DEVAZEPIDE; PEGYLATED CHOLECYSTOKININ 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; FOOD INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SATIETY; WISTAR RAT;

ANIMALS; ANOREXIA; APPETITE DEPRESSANTS; ASPARTIC ACID; BLOOD-BRAIN BARRIER; CHOLECYSTOKININ; DELAYED-ACTION PREPARATIONS; DEVAZEPIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; INJECTIONS, INTRAPERITONEAL; MALE; NAPHTHALENESULFONATES; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; SATIATION;

EID: 34848909650     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707390     Document Type: Article

References (39)

1. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977a). Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252: 3582-3586.
2. Abuchowski A, van Es T, Palczuk NC, Davis FF (1977b). Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252: 3578-3581.
3. Ankeny DP, McTigue DM, Guan Z, Yan Q, Kinstler O, Stokes BT et al. (2001). Pegylated brain-derived neurotrophic factor shows improved distribution into the spinal cord and stimulates locomotor activity and morphological changes after injury. Exp Neurol 170: 85-100.
4. Bado A, Durieux C, Moizo L, Roques BP, Lewin MJ (1991). Cholecystokinin-A receptor mediation of food intake in cats. Am J Physiol 260: 693-697.
5. Baldwin BA, de la Riva C, Gerskowitch VP (1994). Effect of a novel CCKA receptor antagonist (2-NAP) on the reduction in food intake produced by CCK in pigs. Physiol Behav 55: 175-179.
6. Baldwin BA, Parrott RF, Ebenezer IS (1998). Food for thought: a critique on the hypothesis that endogenous cholecystokinin acts as a physiological satiety factor. Prog Neurobiol 55: 477-507.
7. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP et al. (2001). Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18: 1157-1166.
8. Cokelaere MM, Busselen P, Flo G, Daenens P, Decuypere E, Kuhn E et al. (1995). Devazepide reverses the anorexic effect of simmondsin in the rat. J Endocrinol 147: 473-477.
9. Covasa M, Forbes JM (1994). Effects of the CCK receptor antagonist MK-329 on food intake in broiler chickens. Pharmacol Biochem Behav 48: 479-486.
10. De Cuyper M, Lievens S, Flo G, Cokelaere M, Peleman C, Martins F et al. (2004). Receptor-mediated biological responses are prolonged using hydrophobized ligands. Biosens Bioelectron 20: 1157-1164.
11. Ebenezer IS (2003). The effects of a peripherally acting cholecystokinin1 receptor antagonist on food intake in rats: implications for the cholecystokinin-satiety hypothesis. Eur J Pharmacol 461: 113-118.
12. Ebenezer IS, Baldwin BA (1995). 2-Naphthalenesulphonyl-L-aspartyl-2-(phenethyl) amide (2-NAP) and food intake in rats: evidence that endogenous peripheral CCK does not play a major role as a satiety factor. Br J Pharmacol 116: 2371-2374.
13. Ebenezer IS, de la Riva C, Baldwin BA (1990). Effects of the CCK receptor antagonist MK-329 on food intake in pigs. Physiol Behav 47: 145-148.
14. Ebenezer IS, Parrott RF (1993). A70104 and food intake in pigs: implication for the CCK 'satiety' hypothesis. NeuroReport 4: 495-498.
15. Flo G, Van Boven M, Vermaut S, Daenens P, Decuypere E, Cokelaere M (2000). The vagus nerve is involved in the anorexigenic effect of simmondsin in the rat. Appetite 34: 147-151.
16. Flo G, Vermaut S, Darras VM, Van Boven M, Decuypere E, Kuhn ER et al. (1999). Effects of simmondsin on food intake, growth, and metabolic variables in lean (+/?) and obese (fa/fa) Zucker rats. Br J Nutr 81: 159-167.
17. Flo G, Vermaut S, Van Boven M, Daenens P, Buyse J, Decuypere E et al. (1998). Comparison of the effects of simmondsin and cholecystokinin on metabolism, brown adipose tissue and the pancreas in food-restricted rats. Horm Metab Res 30: 504-508.
18. Harris JM, Chess RB (2003). Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221.
19. Harris JM, Martin NE, Modi M (2001). Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539-551.
20. Hewson G, Leighton GE, Hill RG, Hughes J (1988). The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol 93: 79-84.
21. Hull RA, Shankley NP, Harper EA, Gerkowitch VP, Black JW (1993). 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP) - a selective cholecystokinin CCKA-receptor antagonist. Br J Pharmacol 108: 734-740.
22. Ivy AC, Oldberg E (1927). Contraction and evacuation of gall-bladder caused by a highly purified 'secretin' preparation. Proc Soc Exp Biol Med 25: 113-115.
23. Koulischer D, Moroder L, Deschodt-Lanckman M (1982). Degradation of cholecystokinin octapeptide, related fragments and analogs by human and rat plasma in vitro. Regul Pept 4: 127-139.
24. León-Tamariz F, Verbaeys I, VanBoven M, DeCuyper M, Buyse J, Clynen E et al. (2007). PEGylation of cholecystokinin prolongs its anorectic effect in rats. Peptides 28: 1003-1011.
25. Lievens S, Flo G, Decuypere E, Van Boven M, Cokelaere M (2003). Simmondsin: effects on meal patterns and choice behavior in rats. Physiol Behav 78: 669-677.
26. MacKay JA, Deen DF, Szoka FC (2005). Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 1035: 139-153.
27. Passaro EJr, Debas H, Oldendorf W, Yamada T (1982). Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. Brain Res 241: 335-340.
28. Pullen RG, Hodgson OJ (1987). Penetration of diazepam and the non-peptide CCK antagonist, L-364,718, into rat brain. J Pharm Pharmacol 39: 863-864.
29. Reidelberger RD, Castellanos DA, Hulce M (2003). Effects of peripheral CCK receptor blockade on food intake in rats. Am J Physiol Regul Integr Comp Physiol 285: R429-R437.
30. Reidelberger RD, Varga G, Solomon TE (1991). Effects of selective cholecystokinin antagonists L364,718 and L365,260 on food intake in rats. Peptide 12: 1215-1221.
31. Roberts MJ, Bentley MD, Harris JM (2002). Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54: 459-476.
32. Smith GP, Gibbs J (1992). Role of CCK in satiety and appetite control. Clin Neuropharmacol 15: 476A.
33. Smith GP, Gibbs J (1994). Satiating effect of cholecystokinin. Ann NY Acad Sci 713: 236-241.
34. Veronese FM, Pasut G (2005). PEGylation, successful approach to drug delivery. Drug Discov Today 10: 1451-1458.
35. Weatherford SC, Chiruzzo FY, Laughton WB (1992). Satiety induced by endogenous and exogenous cholecystokinin is mediated by CCK-A receptors in mice. Am J Physiol 262: 574-578.
36. Weatherford SC, Laughton WB, Salabarria J, Danho W, Tilley JW, Netterville LA et al. (1993). CCK satiety is differentially mediated by high- and low-affinity CCK receptors in mice and rats. Am J Physiol 264: 244-249.
37. Weller A, Smith GP, Gibbs J (1990). Endogenous cholecystokinin reduces feeding in young rats. Science 247: 1589-1591.
38. Woltman TA, Hulce M, Reidelberger RD (1999). Relative blood-brain barrier permeabilities of the cholecystokinin receptor antagonists devazepide and A-65186 in rats. J Pharm Pharmacol 51: 917-920.
39. Wu D, Pardridge WM (1999). Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA 96: 254-259.